Unrefined Salmon Oil as Dietary Supplement in Patient With Chronic Obstructive Pulmonary Disease
← catalyst calendarNCT05130294 · readout ≤ 102 d
Sponsored by Hofseth Biocare ASA (industry) · HBC.OL — their whole pipeline →. With Møre og Romsdal Hospital Trust.
Phase
Not applicable
Status
Withdrawn
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
0actual
Sites
1
Country
Norway
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was terminated before recruitment began due to administrative decision.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2025 | estimated | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease
Interventions
- Dietary supplement: CARDIO®
- Dietary supplement: Placebo
Primary outcome
what the primary-completion date above is the date OFLevel of oxidative low-density lipoprotein (ox-LDL)
measured Day 0 (baseline) to week 20.
Permalink · HBC.OL's whole pipeline · Catalyst calendar · Every registered study · What changed